Toggle Health Problems and D

Colitis treated by activated vitamin D getting into the colon via emulsion (mice) – July 2018

Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease.

J Control Release. 2018 Jul 12. pii: S0168-3659(18)30413-9. doi: 10.1016/j.jconrel.2018.07.019
Zai K1, Hirota M2, Yamada T2, Ishihara N2, Mori T3, Kishimura A4, Suzuki K2, Hase K5, Katayama Y6.
 Download the PDF from VitaminDWiki
Abstract is below the following box


Much more benefit when a drug can be delivered exactly to where it is needed
Much better than increasing Vitamin D levels for the entire body
Other examples for Vitamin D targeted delivery include topical for skin and oral for gums
Respiratory vitamin D (inhaled) looks very promising

See also VitaminDWiki


Activated Vitamin D

click on chart for details

Spleen was not as enlarged with activated vitamin D emulsion

The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

Created by admin. Last Modification: Saturday January 18, 2020 04:01:49 GMT-0000 by admin. (Version 11)

Attached files

ID Name Comment Uploaded Size Downloads
13357 Mice nano.pdf admin 18 Jan, 2020 926.60 Kb 1972
10236 Splene colitis.jpg admin 24 Jul, 2018 9.09 Kb 633